AbbVie appoints Roopal Thakkar as EVP, Research & Development and Chief Scientific Officer
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Shares and American Depositary Shares of Olink for $26.00 per Share
The academy has secured partnerships with 15 esteemed hospitals
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
The integration of SAP S/4HANA Cloud will equip Cupid Limited with a comprehensive suite of integrated applications,
Ibara will drive AI-powered clinical research innovation
Subscribe To Our Newsletter & Stay Updated